Interleukin-6 and chronic inflammation
By C. Gabay. Arthritis Research & Therapy, 2006
1,438 citations recorded by the source corpus.
Interleukin (IL)-6 is produced at the site of inflammation and plays a key role in the acute phase response as defined by a variety of clinical and biological features such as the production of acute phase proteins. IL-6 in combination with its soluble receptor sIL-6Rα, dictates the transition from acute to chonic inflammation by changing the nature of leucocyte infiltrate (from polymorphonuclear neutrophils to monocyte/macrophages). In addition, IL-6 exerts stimulatory effects on T- and B-cells, thus favoring chronic inflammatory responses. Strategies targeting IL-6 and IL-6 signaling led to effective prevention and treatment of models of rheumatoid arthritis and other chronic inflammatory diseases.
Subfields: Immunology, Oncology, Rheumatology
View Paper: https://www.semanticscholar.org/paper/38834b81ecbc03bfb38e481c04ce28b86c0eeece
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
In Oncology
In Rheumatology
Citations in the corpus
- Role of inflammation in the pathogenesis of osteoarthritis: latest findings and interpretations (2013, background): “Elevated at sites of inflammation, IL-6 has been shown to activate B cells, T cells, and mediate the recruitment of inflammatory cells to sites of inflammation [Gabay, 2006].”
- Obesity and inflammation: the linking mechanism and the complications (2016, neutral): “Gabay [46] IL-6 Rheumatoid arthritis”